Bluebird Common Stock Total Equity from 2010 to 2024
| BLUE Stock | USD 0.42 0.01 2.44% |
Common Stock Total Equity | First Reported 2012-12-31 | Previous Quarter 1.1 M | Current Value 1.1 M | Quarterly Volatility 221.8 K |
Check Bluebird Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bluebird Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8 M, Interest Expense of 31.6 M or Selling General Administrative of 126.8 M, as well as many indicators such as Price To Sales Ratio of 4.88, Dividend Yield of 0.0 or PTB Ratio of 0.46. Bluebird financial statements analysis is a perfect complement when working with Bluebird Bio Valuation or Volatility modules.
Bluebird | Common Stock Total Equity |
Latest Bluebird Bio's Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Bluebird bio over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Bluebird Bio's Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bluebird Bio's overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Bluebird Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 418,403 | |
| Geometric Mean | 168,335 | |
| Coefficient Of Variation | 63.73 | |
| Mean Deviation | 211,176 | |
| Median | 431,400 | |
| Standard Deviation | 266,651 | |
| Sample Variance | 71.1B | |
| Range | 815.6K | |
| R-Value | 0.89 | |
| Mean Square Error | 15.9B | |
| R-Squared | 0.79 | |
| Slope | 53,085 | |
| Total Sum of Squares | 995.4B |
Bluebird Common Stock Total Equity History
About Bluebird Bio Financial Statements
Bluebird Bio stakeholders use historical fundamental indicators, such as Bluebird Bio's Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Although Bluebird Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bluebird Bio's assets and liabilities are reflected in the revenues and expenses on Bluebird Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bluebird bio. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 817.6 K | 431.4 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bluebird bio is a strong investment it is important to analyze Bluebird Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bluebird Bio's future performance. For an informed investment choice regarding Bluebird Stock, refer to the following important reports:Check out the analysis of Bluebird Bio Correlation against competitors. For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.80) | Revenue Per Share 0.357 | Quarterly Revenue Growth 1.337 | Return On Assets (0.36) | Return On Equity (1.87) |
The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.